Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$35.77M-32.34%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey Allen Willard
- Sector
- Consumer Cyclical
- Industry
- Specialty Retail
- Employees
- 189
- Beta
- 0.83
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.93
Financials
Revenue
$35.77M-32.3%Net Income
$-6.43M-233.4%EBITDA
$-4.24M-152.2%Free Cash Flow
$-1.64MEPS (diluted)
$-0.31-229.2%Shares Outstanding (diluted)
21.07M+3.3%Operating Expenses
$14.04MCash & Debt
$11.42MReturn of Capital
$5.0KRevenue by Segment (annual)
$2.30MDividend per Share
$0.30Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $179.02M | $-57.29M | $-2.74 |
| 2025 | $226.97M | $-6.27M | $-0.30 |
| 2024 | $274.10M | $-7.46M | $-0.37 |
| 2023 | $256.58M | $5.14M | $0.25 |
| 2022 | $273.42M | $21.10M | $1.05 |
| 2021 | $303.58M | $23.92M | $1.53 |
| 2020 | $284.13M | $25.85M | $1.29 |
| 2019 | $283.42M | $37.74M | $1.84 |
| 2018 | $273.80M | $37.28M | $1.83 |
| 2017 | $249.18M | $23.82M | $1.18 |
| 2016 | $234.68M | $20.57M | $1.02 |
| 2015 | $229.40M | $17.45M | $0.87 |
| 2014 | $233.39M | $17.97M | $0.90 |
| 2013 | $227.83M | $17.16M | $0.86 |
Valuation
PETShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·12d ago·Neutral
PetMed Express, Inc. (PETS) Q2 2027 Earnings Call Prepared Remarks Transcript PetMed Express, Inc. (PETS) Q2 2027 Earnings Call Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
PetMeds® Announces Second Quarter Financial Results DELRAY BEACH, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…sults on Tuesday, November 10, 2026 DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year ended September 30, 2026, on Tuesday, November 10, 2026 after market close. The Company will host a conference call and webcast to review these results at 4:30pm Eastern Time on the same day.
View source ↗ - Newsglobenewswire.com·66d ago·Neutral
PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
PetMeds Appoints Andrew Parry as Chief Technology Officer DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company's technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.
View source ↗ - Newszacks.com·100d ago·Neutral
PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y PETS' fiscal first-quarter 2027 sales decline year over year, but lower costs, stronger recurring sales and new partnerships offer signs of progress.
View source ↗ - Newszacks.com·101d ago·Negative
PetMed (PETS) Reports Q1 Loss, Misses Revenue Estimates PetMed (PETS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of $0.12. This compares to a loss of $0.34 per share a year ago.
View source ↗ - Newsseekingalpha.com·101d ago·Neutral
PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $-0.16 per share
Typical surprise -333.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.31 vs $-0.11miss
- Thu, Aug 13$-0.28 vs $0.12miss
- Tue, Jun 2$-0.19 vs $-0.18miss
- Thu, Feb 5$-0.50 vs $-0.06miss
- Fri, Dec 19$-0.34 vs $-0.02miss
- Tue, Sep 30$-0.07 vs $-0.06miss
Estimates and results for PETS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PETS officers and directors.
- Bought
- $4.0m
- Sold
- $202k
35 trades
3 trades
- Nina Capital Holdings Inc.bought
- Silvercape Investments Ltdbought
- Silvercape Investments Ltdbought
- Nina Capital Holdings Inc.bought
- Silvercape Investments Ltdbought
- Silvercape Investments Ltdbought
- Silvercape Investments Ltdbought
- Silvercape Investments Ltdbought
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PETS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
